Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed (2016 - 2025)

Arrowhead Pharmaceuticals' Return on Capital Employed history spans 15 years, with the latest figure at 0.26% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 90.0% year-over-year to 0.26%; the TTM value through Dec 2025 reached 0.26%, up 90.0%, while the annual FY2025 figure was 0.09%, 80.0% up from the prior year.
  • Return on Capital Employed reached 0.26% in Q4 2025 per ARWR's latest filing, up from 0.08% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.26% in Q4 2025 to a low of 0.67% in Q2 2024.
  • Average Return on Capital Employed over 5 years is 0.29%, with a median of 0.26% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: plummeted -47bps in 2024, then surged 90bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.35% in 2021, then surged by 33bps to 0.23% in 2022, then tumbled by -102bps to 0.47% in 2023, then crashed by -34bps to 0.64% in 2024, then skyrocketed by 141bps to 0.26% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Return on Capital Employed are 0.26% (Q4 2025), 0.08% (Q3 2025), and 0.08% (Q2 2025).